Literature DB >> 23072715

Depression and pain among inpatients with spinal cord injury and spinal cord disease: differences in symptoms and neurological function.

Denise G Tate1, Martin B Forchheimer, Dunia Karana-Zebari, Anthony E Chiodo, Jennifer Young Kendall Thomas.   

Abstract

PURPOSE: To examine the relationship between depression and pain severity during inpatient rehabilitation for those with new onset of spinal cord injury or spinal cord disease (SCI/D), along with patient characteristics, neurological function and etiology.
METHOD: This cross-sectional study reviewed medical records of 100 adults with SCI/D including their admission scores on the Patient Health Questionnaire 9 (PHQ-9), a measure of depression, and pain ratings collected at admission and discharge.
RESULTS: Upon admission, 28% reported moderate-to-severe symptoms of depression and 69% reported pain. PHQ-9 scores were associated with pain only among those with the least severe impairments, for whom higher scores were associated with greater pain. While depression levels did not differ by etiology, those with traumatic injuries had higher pain ratings.
CONCLUSIONS: In general, depressive symptoms were not associated with pain severity in this sample. Etiology was associated with pain, those with traumatic SCI reporting more pain at admission. Among demographic characteristics, age was related to pain, with younger subjects reporting higher levels. These findings suggest that certain characteristics may predispose patients to pain and depression upon admission to rehabilitation. By determining who is at risk for these symptoms, clinicians can adopt treatments that prevent these from becoming chronic conditions.

Entities:  

Mesh:

Year:  2012        PMID: 23072715     DOI: 10.3109/09638288.2012.726692

Source DB:  PubMed          Journal:  Disabil Rehabil        ISSN: 0963-8288            Impact factor:   3.033


  7 in total

1.  Depressive mood in adults with spinal cord injury as they transition from an inpatient to a community setting: secondary analyses from a clinical trial.

Authors:  A Craig; R Guest; Y Tran; J Middleton
Journal:  Spinal Cord       Date:  2017-05-02       Impact factor: 2.772

2.  Depression, pain intensity, and interference in acute spinal cord injury.

Authors:  Linton Cuff; Jesse R Fann; Charles H Bombardier; Daniel E Graves; Claire Z Kalpakjian
Journal:  Top Spinal Cord Inj Rehabil       Date:  2014

3.  Contextualizing the lived experience of quality of life for persons with spinal cord injury: A mixed-methods application of the response shift model.

Authors:  Edward J Rohn; Denise G Tate; Martin Forchheimer; Lisa DiPonio
Journal:  J Spinal Cord Med       Date:  2018-09-06       Impact factor: 1.985

Review 4.  Multiple organ dysfunction and systemic inflammation after spinal cord injury: a complex relationship.

Authors:  Xin Sun; Zachary B Jones; Xiao-Ming Chen; Libing Zhou; Kwok-Fai So; Yi Ren
Journal:  J Neuroinflammation       Date:  2016-10-06       Impact factor: 8.322

5.  The efficacy of GABAergic precursor cells transplantation in alleviating neuropathic pain in animal models: a systematic review and meta-analysis.

Authors:  Shaghayegh Askarian-Amiri; Solmaz Nasseri Maleki; Seyedeh Niloufar Rafiei Alavi; Arian Madani Neishaboori; Amirmohammad Toloui; Mohammed I M Gubari; Arash Sarveazad; Mostafa Hosseini; Mahmoud Yousefifard
Journal:  Korean J Pain       Date:  2022-01-01

6.  Human bone marrow-derived and umbilical cord-derived mesenchymal stem cells for alleviating neuropathic pain in a spinal cord injury model.

Authors:  Mahmoud Yousefifard; Farinaz Nasirinezhad; Homa Shardi Manaheji; Atousa Janzadeh; Mostafa Hosseini; Mansoor Keshavarz
Journal:  Stem Cell Res Ther       Date:  2016-03-08       Impact factor: 6.832

7.  Self-management of pain and depression in adults with spinal cord injury: A scoping review.

Authors:  Lauren Cadel; Claudia DeLuca; Sander L Hitzig; Tanya L Packer; Aisha K Lofters; Tejal Patel; Sara J T Guilcher
Journal:  J Spinal Cord Med       Date:  2018-10-18       Impact factor: 1.985

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.